Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion.


Journal

Documenta ophthalmologica. Advances in ophthalmology
ISSN: 1573-2622
Titre abrégé: Doc Ophthalmol
Pays: Netherlands
ID NLM: 0370667

Informations de publication

Date de publication:
08 2019
Historique:
received: 07 12 2018
accepted: 02 04 2019
pubmed: 14 4 2019
medline: 31 8 2019
entrez: 14 4 2019
Statut: ppublish

Résumé

To determine the physiology of the macula by the focal macular electroretinograms (fmERGs) in patients with branch retinal vein occlusion with macular edema (BRVOME) treated by intravitreal injections of ranibizumab (IVR). We studied 17 eyes of 17 patients with BRVOME. The contralateral unaffected eyes served as controls. All patients were treated with an IVR at monthly intervals for 3 consecutive months. The baseline best-corrected visual acuity (BCVA), optical coherence tomographic (OCT) findings, and fmERGs were compared to the post-treatment values. The fmERGs were elicited by a 15° circular spot or a superior or inferior semicircular spot. The center of the spot was placed on the fovea. The amplitudes of the a- and b-waves, photopic negative response (PhNR), and sum of the oscillatory potentials (ΣOPs: sum of OP1, OP2, and OP3 amplitudes) were measured. In addition, the implicit times of the a- and b-waves were also measured. The BCVA improved significantly from 0.39 ± 0.28 logMAR units to 0.17 ± 0.18 logMAR units after the resolution of the central macular edema (P < 0.01). All components of the fmERGs elicited by the semicircular stimulus spot placed on the occluded side were smaller than that elicited from the corresponding area of the control eyes. The b-wave amplitudes increased significantly from 0.49 ± 0.25 to 0.75 ± 0.36 µV following the IVR injections, but the amplitudes of the a-wave and PhNR remained reduced (P < 0.05). The amplitudes of the PhNR and ΣOPs elicited by stimulating the non-occluded side were reduced with relative preservation of the a- and b-waves (P < 0.05). They recovered after the treatment from 0.27 ± 0.15 to 0.50 ± 0.30 and 0.33 ± 0.15 to 0.53 ± 0.19 µV, respectively. IVRs improved the macular function not only on the occluded side but also on the non-occluded side. On the occluded side, the BRVOME affects the function of all retinal layers of the macula. Even after the IVR, the function of the photoreceptors and retinal ganglion cells remained abnormal. On the non-occluded side, the inner retinal function improved after the IVR.

Identifiants

pubmed: 30980231
doi: 10.1007/s10633-019-09696-5
pii: 10.1007/s10633-019-09696-5
doi:

Substances chimiques

Angiogenesis Inhibitors 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0
Ranibizumab ZL1R02VT79

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-74

Références

Invest Ophthalmol Vis Sci. 1989 Aug;30(8):1743-9
pubmed: 2759790
Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1267-74
pubmed: 26383643
Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):5905-9
pubmed: 21693603
Jpn J Ophthalmol. 2006 Jul-Aug;50(4):367-373
pubmed: 16897223
Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3544-50
pubmed: 18441308
Am J Ophthalmol. 2016 Jun;166:76-83
pubmed: 27038893
PLoS One. 2016 Sep 12;11(9):e0162533
pubmed: 27618696
Am J Ophthalmol. 2007 Feb;143(2):342-4
pubmed: 17258527
Ophthalmology. 2016 Feb;123(2):330-6
pubmed: 26522708
Ophthalmology. 2010 Jun;117(6):1102-1112.e1
pubmed: 20398941
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5636-44
pubmed: 18641287
Jpn J Ophthalmol. 2019 Jan;63(1):90-99
pubmed: 30470956
Invest Ophthalmol Vis Sci. 2011 Oct 11;52(11):8047-55
pubmed: 21911591
Nippon Ganka Gakkai Zasshi. 1988 Sep;92(9):1419-49
pubmed: 3063099
BMC Ophthalmol. 2016 May 25;16:61
pubmed: 27225268
Graefes Arch Clin Exp Ophthalmol. 2015 Aug;253(8):1201-9
pubmed: 25163415
Invest Ophthalmol Vis Sci. 1988 Nov;29(11):1631-5
pubmed: 3182198
Invest Ophthalmol Vis Sci. 2013 Nov 01;54(12):7207-14
pubmed: 24106117
Curr Eye Res. 2015 Apr;40(4):439-49
pubmed: 24871085
Vision Res. 2008 Jan;48(2):273-80
pubmed: 18158169

Auteurs

Tomoharu Nishimura (T)

Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshiagya, Koshigaya, 343-8555, Saitama, Japan.

Shigeki Machida (S)

Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshiagya, Koshigaya, 343-8555, Saitama, Japan. machidas@dokkyomed.ac.jp.

Atsushi Tada (A)

Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshiagya, Koshigaya, 343-8555, Saitama, Japan.

Eiki Oshida (E)

Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshiagya, Koshigaya, 343-8555, Saitama, Japan.

Tetsuya Muto (T)

Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshiagya, Koshigaya, 343-8555, Saitama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH